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Abstract
SRTR report cards provide the basis for quality measurement of US transplant centers. There is 
limited data evaluating the prognostic value of report cards, informing whether they are predictive 
of prospective patient outcomes. Using national SRTR data, we simulated report cards and 
calculated Standardized Mortality Ratios(SMR) for kidney transplant centers over five distinct 
eras. We ranked centers based on SMR and evaluated outcomes for patients transplanted the year 
following reports. Recipients transplanted at the 50th, 100th and 200th ranked centers had 18%
(AHR=1.18,1.13–1.22), 38%(AHR=1.38,1.28–1.49) and 91%(AHR=1.91,1.64–2.21) increased 
hazard for one-year mortality relative to recipients at the top-ranked center. Risks were attenuated 
but remained significant for long-term outcomes. Patients transplanted at centers meeting low-
performance criteria in the prior period had 40%(AHR=1.40,1.22–1.68) elevated hazard for one-
year mortality in the prospective period. Centers’ SMR from the report card was highly 
predictive(c-statistics>0.77) for prospective center SMRs and there was significant correlation 
between centers’ SMR from the report card period and the year following(ρ=0.57, p<0.001). 
Although results do not mitigate potential biases of report cards for measuring quality, they do 
indicate strong prognostic value for future outcomes. Findings also highlight that outcomes are 
associated with center ranking across a continuum rather than solely at performance margins.
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Introduction
Report cards for transplant centers are publicly available on a biannual basis published by 
the Scientific Registry of Transplant Recipients (SRTR). SRTR report cards provide detailed 
information about recipient and donor characteristics for each US transplant center as well 
as risk adjusted outcomes (1). In recent years, these report cards have received increased 
prominence due to the Conditions of Participation issued by the Centers for Medicaid and 
Medicare Services (CMS) which details an explicit association between public funding of 
transplant programs with outcomes of SRTR report cards (2). Issues regarding the 
appropriate development, use and interpretation of report cards are contentious in the 
transplant community (3). Debates surrounding report cards include understanding the 
appropriate balance between centers’ resource limitations to collect additional data used for 
risk adjustment and the need to improve the predictive value of models for accurate quality 
measurement of centers (3;4).
Report cards in healthcare may serve an important role of quality assurance and 
identification of best practices but have been criticized for lack of appropriate risk 
adjustment, ineffective dissemination of results to patients and unintended consequences 
such as limiting care for high risk or vulnerable patients (5–9). In transplantation, the 
regulatory perspective includes the viewpoint that report cards can be valuable tools for 
quality improvement initiatives (10–12). SRTR report cards have been shown to influence 
patient registration at transplant centers suggesting that patients and/or insurance companies 
utilize report cards for decision-making purposes (13;14). However, there are concerns 
about the appropriate use and impact of SRTR report cards based on documented biases, 
poor discriminatory power, the potential to stifle innovation and associations of low 
performance evaluations with reductions in transplant volume (15–21).
One aspect of transplant center report cards that has not been thoroughly investigated is the 
reliability of report cards over time. There is an implicit assumption that center outcomes as 
reflected in SRTR report cards not only describe past performance but are a reasonable 
proxy for prospective center quality. However, it is not clear if report cards derived over a 
fixed period are useful indicators of outcomes for prospective patients. If in fact report cards 
are highly predictive of prospective outcomes, this would suggest that measured center 
quality is relatively stable and report cards may be used with greater confidence to guide 
quality initiatives or decision-making tools for patients. In contrast, if there are significant 
fluctuations in measured quality, decisions or policies based on report cards may be less 
useful in practice.
In this study, our primary aim was to evaluate the prognostic value of report cards for kidney 
transplant centers in the United States. We evaluated the degree to which kidney transplant 
recipient survival was associated with report cards from prior periods and whether this 
association was consistent for short and long-term outcomes. In addition, we investigated 
whether the association of report cards with prospective outcomes was consistent for 
different subgroups of patients, by center volume as well as whether there was an 
association of recipient outcomes with centers that received prior flags for poor 
performance. Finally, we evaluated the relationship between centers’ standardized mortality 
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ratios (SMR) for the report card period with the center SMR for the year following the 
report card.
Methods
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The 
SRTR data system includes data on all donor, wait-listed candidates, and transplant 
recipients in the US, submitted by the members of the Organ Procurement and 
Transplantation Network (OPTN), and has been described elsewhere (reference). The Health 
Resources and Services Administration (HRSA), U.S. Department of Health and Human 
Services provides oversight to the activities of the OPTN and SRTR contractors (22). The 
primary study population consisted of 63,128 adult primary kidney transplant recipients 
transplanted in five eras (1/1999-12/1999, 7/2001-6/2002, 1/2004-12/2004, 7/2007-6/2008, 
and 1/2009-12/2009). The eras represented recipients transplanted within one year following 
public release of Program-Specific Reports (PSR) based on standard SRTR timelines. For 
example, outcomes for patients transplanted in 1999 were evaluated based on the simulated 
December, 1998 SRTR report, which included a 2 ½ year cohort of patients transplanted 
between July, 1995 and December, 1997. We simulated the SRTR report cards methodology 
for each 2 ½ year cohort and calculated the observed and expected events for each transplant 
center. As SRTR models for mortality exclude re-transplant recipients, we also excluded 
these patients from the analyses. Consistent with SRTR methodology, we used adjusted Cox 
proportional hazard models including factors in the most recent PSR including donor and 
recipient demographic characteristics, primary cause of end-stage renal disease, recipient 
body mass index, recipient primary insurance, HLA-mismatching, panel reactive antibody 
level, waiting time on dialysis, cold ischemia time, donor cause of death, donor history of 
hypertension and diabetes, pump usage, expanded criteria donor status (in the deceased 
donor models for the latter six variables) and donor relationship type (for the living donor 
model only). Although inclusion of some variables has changed over time, we assumed the 
effect of variables inclusion/exclusion on report card evaluations was minimal. Also 
consistent with SRTR methodology, we developed models for living and deceased donors 
separately and combined results of observed and expected events to calculate Standardized 
Mortality Ratios (SMR). We also generated models for graft loss (defined as the composite 
event of death, re-transplantation or return to dialysis) as the outcome in which we included 
re-transplant recipients. For all models, we excluded patients transplanted at centers with 
less than ten transplants based on current policies for review of small programs and 
instability of SMR as a performance metric at this volume. To evaluate the effect of report 
cards on prospective outcomes, we combined recipients over each era. In these models, In 
order to account for clustering of patients within centers we utilized the robust sandwich 
estimator for the Cox proportional hazard models to adjust variance estimates accordingly 
(23).
The primary exposure variable for the statistical models was the center SMR generated from 
the risk adjusted Cox proportional hazard models for one-year mortality and graft loss. We 
ranked centers using the SMR for each period and examined patient outcomes relative to the 
center ranking from the report preceding their transplant date. In order to evaluate whether 
the effect of center ranking was different by center volume, we stratified models by quartile 
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of volume and tested the effects in each group. We also tested whether effects of center 
ranking were consistent by recipient, donor and transplant characteristics. For these models 
we included an interaction term of the applicable characteristic by center rank and tested the 
effect of the interaction in the Cox models. Centers were defined as flagged for low 
performance if they met the three rules currently used by the SRTR which included: a 
SMR>1.5, observed-expected events>3 and an SMR statistically significantly difference 
from one based on a Poisson test. We developed logistic models to evaluate the probability 
that a center would have a SMR exceeding different thresholds the year following the report 
card based on the SMR in the prior period. In addition, we calculated the correlation 
(Spearman’s) between centers’ SMR from the report card period and the year following the 
report card. All analyses were conducted in SAS (v.9.2, Cary, N.C.).
Results
There were 233 transplant centers in the study population. The distribution of patient 
characteristics based on quartile of center ranking is displayed in Table 1. Of note, although 
some comparisons were statistically significant, there were only mild differences in the 
composition of risk factors between groups. The median SMRs for centers during the report 
card periods was 0.98 and the 25th and 75th percentiles were equal to 0.69 and 1.23 
respectively. Centers were ranked based on ascending SMR and matched with patients 
transplanted at the same centers the year following the report card.
Center rank had a statistically significant association with prospective recipient outcomes. A 
difference in rank of 40 was associated with a 14% increased hazard for one-year mortality 
(AHR=1.14, 95% CI 1.11–1.17) among recipients in the prospective period. Figure 1 depicts 
the estimated effect of center rank on one-year adjusted mortality for recipients relative to 
the center ranked 1st in the prior period. As illustrated in the figure, this effect equated to a 
38%, 62% and 91% increased mortality hazard associated with the 100th, 150th and 200th 
ranked center for prospective patients. Based on this model, a difference in center rank of 8 
(based on the SMR from the report card) equated to a statistically significantly improved 
survival for recipients in the prospective period. We tested whether there was a non-linear 
(quadratic) effect of center rank but found no significant effect. Center rank contributed 
more to the Likelihood of the Cox model for one year mortality (χ2=74.4, degrees of 
freedom[df]=1) than donor age (χ2=64.3, df=1), recipient race (χ2=34.6, df=1), recipient 
primary insurance (χ2=53.7, df=3), panel reactive antibody level (χ2=14.9, df=1) and 
waiting time on dialysis (χ2=23.2, df=1), but less than recipient age (χ2=298.2, df=1), donor 
type (χ2=181.4, df=1), body mass index (χ2=110.5, df=1) or primary diagnosis (χ2=157.6, 
df=4).
The association of center ranking with long-term mortality was attenuated as compared to 
the one-year model but remained statistically significant. In this model, a rank difference of 
40 centers was associated with a 7% increased hazard (AHR=1.07, 95% C.I. 1.05–1.08). As 
depicted in Figure 2, this equated to an 18%, 28% and 39% increased adjusted hazard for 
patients transplanted at centers ranked 100th, 150th and 200th relative to patients transplanted 
at the top ranked center. We also tested the effect of center rank in each of the five eras 
separately. For one-year mortality, center rank was significantly associated with prospective 
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patient outcomes in each era, however the effect was attenuated over time with estimated 
hazard of center rank (per 40) from earliest to the most recent era as follows: 1.19 (95% C.I. 
1.12–1.28), 1.18 (95% C.I. 1.10–1.26), 1.14 (95% C.I. 1.07–1.21), 1.14 (95% C.I. 1.06–
1.24) and 1.08 (95% C.I. 1.01–1.16).
Prognostic Value of Report Cards by Center Volume
Tables 2a and 2b display the association of center report cards with prospective recipient 
outcomes stratified by center volume quartile. As indicated, there was a relatively consistent 
association of center rank by center volume for the hazards of one-year or long-term graft 
loss or death. The association of center ranking was consistently higher for one-year graft 
loss and death as compared to long-term outcomes but these differences were similar 
between small and large volume centers.
Prognostic Value of Center Rank by Transplant Characteristics
Table 3 displays the association of center rank with the adjusted hazard for one-year and 
long-term mortality by patient characteristics. As indicated in the table, the association of 
center rank was consistent across patient characteristics with the exception that the effect of 
center ranking was significantly higher among publicly-insured patients (AHR=1.16, 95% 
C.I. 1.12–1.20, per 40 center rank) as compared to privately-insured patients (AHR=1.08, 
95% 1.02–1.14, per 40 center rank) for one-year mortality. There were no other statistically 
significant interactions of center ranking with transplant characteristics including recipient 
and donor age, recipient gender, PRA status, HLA-mismatching, recipient primary diagnosis 
or presence of obesity.
Prognostic Value of Center Flagging
Figure 3 displays the association of recipient one-year outcomes with transplantation at 
centers that met any of the three criteria for SRTR low performance flagging (statistical 
significance, SMR >1.5 or observed-expected events > 3) in the prior report card period. 
Thirty and 26% of centers met at least one flagging criterion for one-year mortality and graft 
loss respectively. Patients transplanted at centers that were flagged for poor performance by 
one or more criterion had a significant association with higher adjusted rates of one-year 
outcomes including a 40% increased hazard for one-year death (AHR=1.40, 95% C.I. 1.22–
1.68) for patients transplanted at centers that previously met all three flagging criteria. The 
association with outcomes was relatively similar and not significantly different irrespective 
of whether centers were identified with one or more criterion. The association of flagging 
with long-term graft loss and mortality was reduced compared to one-year outcomes but 
remained significant. Patients transplanted at centers that met one, two and three flagging 
criteria for graft loss in the prior period had a 10% (AHR=1.10, 95% C.I. 1.06–1.15), 21% 
(AHR=1.21, 95% C.I. 1.14–1.29) and 21% (AHR=1.21, 95% C.I. 1.14–1.28) adjusted 
hazard for long-term graft loss and 21% adjusted hazard (AHR=1.21, 95% C.I. 1.13–1.29) 
for long-term mortality among patients transplanted at centers that previously met all three 
flagging criteria.
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Probability of Transplant Center SMR in the Prospective Period
Among the 226 transplant centers included in the study population that also had at least 10 
transplants in the year following the report card, 48% had a SMR>1 (i.e. more observed 
deaths than expected) in the prior period and 50% had SMR>1 in the prospective period. 
Among centers with a SMR>1 in the report card period, 73% had a SMR>1 in the 
prospective period. Similarly, among centers with SMR<1 from the report card period, 72% 
had an SMR<1 in the prospective period (p<0.001). Figure 4 displays the estimated 
likelihood of a SMR exceeding different thresholds for one-year mortality based on the 
SMR in the prior period. For example, for a center with a 0.5 SMR from a report card, the 
estimated probability of a SMR>1 was 20% and a SMR>1.5 4% in the prospective period. 
For a center with a 2.0 SMR in the report card period, the estimated probability of a SMR>1 
was 94% and a SMR>1.5 64% in the prospective period. The concordance indices for each 
of these models were >0.77 and slightly higher for larger centers. The correlation between 
the SMRs for one-year mortality for transplant centers from the report card period and the 
year following the report card was 0.57 (p<0.001, Figure 5). The correlation was relatively 
consistent by center volume but numerically highest among the largest volume centers 
(quartile 4 centers, ρ=0.70).
Discussion
The primary findings of the study are that (1) center ranking based on standardized mortality 
ratios has strong prognostic value for prospective risk-adjusted recipient outcomes (2) the 
association of transplant center rank with prospective outcomes is relatively consistent by 
patient characteristics and center volume and (3) centers which met flagging criteria for poor 
performance are also significantly associated with diminished risk adjusted outcomes for 
prospective patients. Importantly, current flagging rules by the SRTR and CMS only 
identify a small proportion of centers while the association of center ranking with 
prospective patient outcomes is a continuous effect.
There are several potential interpretations of the results of this study. Primarily, results 
indicate that the outcomes of SRTR reports for kidney transplant centers are strong 
indicators of risk adjusted outcomes for the next cohort of transplant recipients. This may 
reflect that center practices are relatively stable and large deviations in outcomes are not 
common for most centers. One of the important utilities of these results is to illustrate that 
center performance is not adequately characterized in a categorical manner (e.g. better or 
worse than expected). Rather, the association of prior performance with prospective 
outcomes appears to be relatively linear and observable across the spectrum of measured 
quality. Furthermore, the magnitude of the relative hazard by center rank is appreciable even 
within centers that are ‘performing as expected’. For example, differences in recipient 
outcomes between the 50th and 100th ranked centers are associated with almost a 20% 
increased hazard and are comparable to differences between the 150th and 200th ranked 
centers, in which only the latter case would centers have been identified for low 
performance based on current CMS and SRTR criteria. Findings also demonstrate that 
centers’ SMRs are highly predictive of prospective SMRs applicable for future reports. Low 
center performance flags based on current rules also portend relatively high risks for 
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prospective recipients transplanted in the next year at these centers. Interestingly, however, 
the additive prognostic value of each of the flagging criterion was minimal as the risks were 
similar whether centers met one or all three of these criteria. Cumulatively, these findings 
suggest that measured performance is unlikely to change in a short duration and is a 
relatively reliable indicator of outcomes for prospective recipients.
One of the unexpected findings of the study was that the relationship between report cards 
and prospective outcomes was relatively consistent by center volume. Both intuitively and 
mathematically, it may have been expected that outcomes from larger centers (with smaller 
variability of estimated performance) would be more reliable indicators of prospective 
outcomes. However, findings from the study indicate that risk adjusted outcomes (i.e. SMRs 
and center ranking) are consistently associated with patient outcomes for both small and 
larger centers and the predictive value of report cards is only slightly larger for the highest 
volume centers. Although wide variations in SMRs might be more expectable for small 
centers, the findings suggest that even for small and moderate volume centers, report cards 
have significant prognostic value. Another interesting result was that, while the prognostic 
value of report cards was significant for each of the eras evaluated, the effect appeared to 
decline over time. It is possible that this reflects more attention to report cards by centers 
due to enhanced regulatory oversight and more rapid response to results of report cards 
(reflected by the reduced effect of prior center ranking). However, this will need to be 
confirmed in future studies, particularly with greater follow up time since the issue of the 
Conditions of Participation by CMS.
The primary findings of the study were also relatively consistent by recipient and 
characteristics. This suggests that, independent of patient acuity and demographic 
characteristics, center performance has a relatively similar prognostic value applicable to all 
patient groups. One might expect that center quality has more of an impact in certain patient 
groups or donor types, but the findings indicate a fairly robust association for all transplant 
types. The exception in this study was a discordant effect of center ranking on patients based 
on their primary source of insurance. Specifically, the effect was more pronounced among 
patients with public insurance. This could suggest the publicly insured patients are more 
highly affected by center quality as compared to privately insured patients and factors that 
explain short-term mortality are different in these groups, however, the effect was not 
significant for long-term mortality and the source of differences in one-year mortality are 
speculative and cannot be clearly defined in this study.
Results of the study have important implications for decision-making among policy makers, 
transplant centers and patients and caregivers. From a policy perspective, findings suggest 
that transplant center report cards are a relatively reliable indicator for purposes of quality 
assurance and improvement efforts. This includes interpretation of metrics in order to 
identify centers with lower performance as well as centers of excellence (i.e. those with 
higher performance). Findings suggest that regulators may have some assurance that 
outcomes summarized by report cards are relatively stable on average and policies for 
identifying poor or exceptional centers are important for prospective patients. The findings 
may also suggest that quality improvement efforts may take significant time to translate into 
improved measured outcomes. From a transplant center perspective, findings also indicate 
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that, on average, risk adjusted outcomes are consistent over time and provide a relatively 
stable indicator of measured performance. This may be important for administrative 
purposes and contract negotiations with private insurance companies as well as identifying 
opportunities to utilize data from report cards to improve care. It should be noted that 
prospective report cards (i.e. subsequent series of SRTR report cards) are likely even more 
stable than the results in the present study given that they include an overlapping cohort of 
patients. Thus, from a centers’ perspective, understanding the source of risk adjusted 
outcomes (either positive or negative) is important and notable alterations in outcomes may 
require significant changes in both practice and time. From a patient perspective, results 
suggest that report cards may be a useful indicator of prospective results and a reliable tool 
to incorporate in decision-making including center selection. In fact, prior studies have 
indicated that center characteristics can have a substantial impact on long-term patient 
prognoses and the present findings validate that selecting centers based on prior outcomes is 
an important consideration (24–27). Results also validate processes to convey prior 
outcomes to prospective patients and enhance transparency and facilitate decision-making. 
Figure 4 illustrates the probability of centers’ prospective SMR to fall in select ranges given 
a SMR from the report card period. By drawing a vertical line from the SMR on the x-axis, 
one can estimate the likelihood that a center would have a prospective SMR in the given 
ranges. It is notable, that large departures in centers’ SMRs are not common but also suggest 
some degree of regression to the mean as centers with low and high SMRs do tend to have 
lower probability of remaining in the extreme ranges.
Despite the relatively strong prognostic value of report cards, it is also important to 
emphasize that the results of this study do not mitigate potential biases with respect to 
measuring quality of care of transplant centers. An important distinction for the 
interpretation of the findings of this study is that while report cards do appear to be highly 
predictive of prospective risk-adjusted survival, the findings do not provide any evidence as 
to the accuracy or precision of report cards with actual quality of care. In fact, there have 
been a number of studies documenting factors that may be systematically different between 
transplant centers that are not accounted for in SRTR report cards that can impact accurate 
measures of quality (18;28–31). In addition, the predictive value of models used to generate 
report cards (concordance indices ranging from 0.61–0.68) is relatively low suggesting other 
factors may be related to risk adjusted outcomes besides those factors that are accounted for 
in models (32;33). Thus, even though results of report cards are prognostic for adjusted 
outcomes and measurement of center quality, the same underlying biases that can affect the 
report card could be salient in the prospective period pertinent to this study. Transplant 
centers that have a relatively high presence of underlying (unadjusted) risk factors may 
continuously be ranked lower in any of the risk adjusted analyses irrespective of their true 
quality of care. The results should also be placed in the context that posttransplant risk 
adjusted outcomes may not be the most important factor for candidates selecting a transplant 
center. In fact, a prior study demonstrated that median waiting time had the most 
pronounced association with candidate survival among center characteristics including post-
transplant survival (25). Finally, we did not investigate the prognostic value of report cards 
over longer durations (that may be salient to candidates who are not expected to receive a 
transplant for several years). For patients with extended waiting times, the association of 
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report cards years before their transplant may be less important and future studies examining 
the durability of report cards over time may be important to investigate to help guide 
decision-making. In addition, from a regulatory perspective, these data do not necessarily 
suggest that programs with poor outcomes are destined to produce lower risk adjusted 
outcomes over an extended period, but it is likely that changes in performance that do occur 
will require sufficient follow up time.
In summary, the primary finding of our study is that risk adjusted outcomes used for kidney 
transplant center report cards have strong prognostic value for prospective recipient 
outcomes. Report cards may be viewed as reliable indicators of outcomes for patients 
transplanted at centers in the following year and this association is relatively consistent by 
center volume and patient characteristics. These results have implications for the 
interpretation of report cards for policy makers, transplant centers and patients but should 
also be viewed in the context that results do not obviate sources of bias for measured 
performance. Continued efforts for utilizing report cards to identify best care practices 
among centers and to provide transparent information to patients and caregivers are 
critically important.
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Figure 1. 
Adjusted Hazard for One-Year Mortality based on Center Rank in Prior Report Card Period
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Figure 2. 
Adjusted Hazard for Long-Term Mortality based on Center Rank in Prior Report Card 
Period
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Figure 3. Association of Prior Performance Flagging Criteria on Prospective Outcomes*
* Criteria include statistically significantly worse than expected (one-sided p-value <0.05), 
observed-expected events > 3, observed/expected ratio > 1.5; models adjusted for recipient 
and donor age, gender, race, recipient primary diagnosis, donor type (living or deceased), 
functional status, re-transplantation (for graft loss model only), human leukocyte antigen 
mismatching, recipient panel reactive antibody status, waiting time on dialysis, recipient 
body mass index and recipient primary insurance.
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Figure 4. Probability of Prospective SMRs for Transplant Centers based on SMR from Prior 
Reporting Period
* concordance indices for models evaluating likelihood of center SMR> 0.5, 0.75, 1.0, 1.25 
and 1.5 were 0.77, 0.77, 0.78, 0.80, 0.81 respectively
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Figure 5. Correlation between Transplant Center Standardized Mortality Ratios for Report 
Card and Year following Report Card
note: 4 observations out of range not displayed in graph
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Table 2a
Association of Prior Center SMR on Prognostic Risk for Graft Loss Stratified by Center Volume
Center Volume (from prior report card 
cohort) Adjusted Hazard Ratio associated with Center Rank (per 40) in Prior Reporting Period 
**
One-year Graft Loss (95% C.I.) Long-Term Graft Loss (95% C.I.)
10–129 1.10 (1.06 – 1.14) 1.05 (1.03 – 1.07)
130–211 1.13 (1.09 – 1.17) 1.04 (1.02 – 1.06)
212–352 1.10 (1.05 – 1.15) 1.07 (1.05 – 1.10)
353–820 1.13 (1.09 – 1.18) 1.09 (1.06 – 1.12)
*Center Rank based on SMR for Graft Loss in period prior to transplant
**
Models adjusted for recipient and donor age, gender, race, recipient primary diagnosis, donor type (living or deceased), functional status, re-
transplantation, human leukocyte antigen mismatching, recipient panel reactive antibody status, waiting time on dialysis, recipient body mass index 
and recipient primary insurance.
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Table 2b
Association of Prior Center SMR on Prognostic Risk for Patient Death Stratified by Center Volume
Center Volume (from prior report card 
cohort) Adjusted Hazard Ratio associated with Center Rank (per 40) in Prior Reporting Period 
**
One-year Death (95% C.I.) Long-Term Death (95% C.I.)
10–129 1.14 (1.09 – 1.19) 1.06 (1.04 – 1.08)
130–211 1.15 (1.08 – 1.23) 1.07 (1.04 – 1.11)
212–352 1.14 (1.07 – 1.22) 1.08 (1.05 – 1.12)
353–820 1.12 (1.04 – 1.20) 1.08 (1.05 – 1.12)
*Center Rank based on SMR for Death in period prior to transplant
**
Models adjusted for recipient and donor age, gender, race, recipient primary diagnosis, donor type (living or deceased), functional status, human 
leukocyte antigen mismatching, recipient panel reactive antibody status, waiting time on dialysis, recipient body mass index and recipient primary 
insurance.
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Table 3
Association of Center Ranking on Post-transplant Outcomes by Transplant Characteristics
Transplant Characteristics Adjusted Hazard Ratio associated with Center Rank (per 40) in Prior Reporting Period*
One-year Mortality (95% C.I.) Long-Term Patient Mortality (95% C.I.)
All patients 1.14 (1.11–1.17) 1.07 (1.05 – 1.08)
Recipients >= 60 years 1.17 (1.12 – 1.22) 1.07 (1.05 – 1.10)
Recipients 18–59 years 1.12 (1.07 – 1.16) 1.06 (1.04 – 1.08)
Recipient BMI >= 30 kg/m2 1.11 (1.06 – 1.18)† 1.07 (1.04 – 1.10) †
Recipients BMI < 30 kg/m2 1.14 (1.09 – 1.18) 1.07 (1.05 – 1.09)
Private Pay Recipients 1.08 (1.02 – 1.14)** 1.05 (1.02 – 1.07)
Non-Private Pay Recipients 1.16 (1.12 – 1.20) 1.08 (1.06 – 1.09)
Deceased Donor Recipients 1.15 (1.12 – 1.19) 1.08 (1.06 – 1.09)
Living Donor Recipients 1.08 (1.01 – 1.15) 1.05 (1.02 – 1.07)
Donor Age >= 60 years 1.07 (0.99 – 1.16) 1.05 (1.01 – 1.09)
Donor Age < 60 years 1.15 (1.11 – 1.19) 1.07 (1.06 – 1.09)
Recipients with Diabetes as PDGN 1.15 (1.10 – 1.20) 1.07 (1.04 – 1.09)
Recipients without Diabetes as PDGN 1.13 (1.09 – 1.18) 1.07 (1.05 – 1.09)
African American Recipients 1.15 (1.09 – 1.22) 1.06 (1.03 – 1.09)
Non-African American Recipients 1.13 (1.09 – 1.17) 1.07 (1.05 – 1.09)
PRA > 0% 1.17 (1.12 – 1.22) 1.07 (1.05 – 1.09)
PRA = 0% 1.10 (1.06 – 1.15) 1.07 (1.04 – 1.09)
Males 1.13 (1.09 – 1.17) 1.08 (1.06 – 1.09)
Females 1.15 (1.09 – 1.21) 1.06 (1.03 – 1.08)
*Center Rank based on SMR for one-year mortality in period prior to transplant; models adjusted for recipient and donor age, gender, race, 
recipient primary diagnosis, donor type (living or deceased), functional status, retransplantation, human leukocyte antigen mismatching, recipient 
panel reactive antibody status, waiting time on dialysis, recipient body mass index and recipient primary insurance.
**p<0.05
†
 Models exclude patients with missing values
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